What is PharmaCyte Biotech, Inc.'s earnings per share (EPS)?

PharmaCyte Biotech, Inc. (PMCB) reported diluted earnings per share of -$2.77 for fiscal year 2026. This represents a -186.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PharmaCyte Biotech, Inc. (PMCB) Financials

PMCB

FY2026 annual

Revenue $0 YoY not available

Net Income -$19.4M -163.4% YoY

EPS (Diluted) -$2.77 -186.8% YoY

Operating Cash Flow -$5.2M -73.0% YoY

Market Cap $3.9M as of Oct 13, 2026

Price / Sales n/m revenue is not positive, FY2026

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 0.1x on $27.5M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jul 31, 2026 Reported Sep 14, 2026 Currency USD FYE April

Newest figures come from the 10-Q for Q1 FY2027, filed Sep 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PMCB SEC filings page.

PharmaCyte Biotech, Inc. (PMCB) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PMCB FY2026 2026-10-04

Development-stage economics remain visible: recurring operating cash outflows persist while reported earnings swing independently of core operations.

FY2025 reported net income of $30.7M coincided with operating cash flow of -$3.0M, then FY2026 returned to a net loss of $19.4M as operating cash flow worsened to -$5.2M. That divergence indicates the FY2025 profit did not reflect a durable improvement in the cash economics of operations.

The operating loss widened from $4.4M in FY2025 to $6.9M in FY2026 while operating cash outflow also increased, showing core spending pressure rather than accounting losses alone. Research and development remained comparatively small at $391K, so reported operating costs were concentrated elsewhere.

Total assets fell from $55.2M to $46.8M while liabilities rose from $3.3M to $11.8M, reducing equity to $33.3M. The combination of shrinking assets, continued operating cash use, and FY2026 financing inflows of $6.6M points to a business funded partly through balance-sheet and capital-structure changes; its reported liquidity measure equaled 43.9 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

PharmaCyte Biotech, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.47

PharmaCyte Biotech, Inc. scores -2.47, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.9M) relative to total liabilities ($11.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

PharmaCyte Biotech, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

PharmaCyte Biotech, Inc. reported a net loss of $19.4M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

PharmaCyte Biotech, Inc. generated $0 in revenue in Q1 2027.

Net Income

-$5.1M

YoY+39.2%

PharmaCyte Biotech, Inc. reported -$5.1M in net income in Q1 2027. This represents an increase of 39.2% from the same quarter a year earlier.

EPS (Diluted)

-$0.54

YoY+56.1%

QoQ-50.0%

PharmaCyte Biotech, Inc. earned -$0.54 per diluted share (EPS) in Q1 2027. This represents an increase of 56.1% from the same quarter a year earlier. Against the prior quarter it is down 50.0%.

EBITDA

Not reported for Q1 2027.

Cash & Balance Sheet

Cash & Debt

$17.7M

YoY+34.6%

QoQ-4.6%

5Y CAGR+79.2%

10Y CAGR+22.5%

PharmaCyte Biotech, Inc. held $17.7M in cash as of Q1 2027; long-term debt is not reported for that period.

Shares Outstanding

11M

YoY+58.0%

QoQ0.0%

5Y CAGR+46.1%

10Y CAGR-35.4%

PharmaCyte Biotech, Inc. had 11M shares outstanding in Q1 2027. This represents an increase of 58.0% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2027.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Return on Equity

-18.5%

YoY+0.7pp

PharmaCyte Biotech, Inc.'s ROE was -18.5% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is up 0.7 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2027.

Operating Margin

Not reported for Q1 2027.

Net Margin

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$60K

YoY-36.9%

PharmaCyte Biotech, Inc. invested $60K in research and development in Q1 2027. This represents a decrease of 36.9% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2027.

Capital Expenditures

Not reported for Q1 2027.

PMCB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMCB quarterly income statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$12K-81.7%	$67K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$10K-50.4%	$19K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$3K-94.6%	$47K
R&D Expenses	N/A	$391K-10.7%	$438K+7.6%	$407K-13.0%	$469K-32.2%	$691K-24.6%	$916K+204.2%	$301K-34.5%	$460K-77.0%	$2.0M+69.0%	$1.2M-16.0%	$1.4M-59.5%	$3.5M+974.8%	$324K	$0	N/A
SG&A Expenses	N/A	$4.9M+24.7%	$3.9M-35.6%	$6.1M+449.4%	$1.1M+2.0%	$1.1M+160.8%	$418K-64.0%	$1.2M-15.7%	$1.4M-24.2%	$1.8M+144.2%	$745K-67.5%	$2.3M+6.0%	$2.2M+12.7%	$1.9M+210.7%	$617K+48.3%	$416K
Operating Income	N/A	-$6.9M-56.6%	-$4.4M+48.6%	-$8.5M-32.0%	-$6.5M-47.0%	-$4.4M-21.2%	-$3.6M+5.3%	-$3.8M+6.7%	-$4.1M+41.3%	-$7.0M-57.2%	-$4.4M+26.9%	-$6.1M+54.2%	-$13.3M+30.1%	-$19.0M-1026.8%	-$1.7M+13.6%	-$1.9M
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.7M+12.5%	-$1.9M
Interest Expense	N/A	N/A	N/A	N/A	$0-100.0%	$509-83.3%	$3K+572.4%	$453	$0	$0-100.0%	$2K+29.2%	$1K-75.9%	$5K-75.3%	$20K-87.1%	$154K-32.9%	$230K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	N/A	-$19.4M-163.4%	$30.7M+9085.0%	$334K+107.7%	-$4.3M-1.8%	-$4.2M-19.4%	-$3.6M+7.2%	-$3.8M+5.9%	-$4.1M+40.4%	-$6.8M-53.7%	-$4.4M+26.7%	-$6.1M+38.9%	-$9.9M+63.6%	-$27.3M-1605.4%	-$1.6M+15.9%	-$1.9M
EPS (Basic)	N/A	-$2.77-186.8%	$3.19+277.2%	-$1.80-718.2%	-$0.22+18.5%	-$0.27+89.0%	-$2.45	N/A	N/A	N/A	N/A	N/A	N/A	-$0.05	$0.00+100.0%	-$0.01
EPS (Diluted)	-$2.31	-$2.77-186.8%	$3.19+277.2%	-$1.80-718.2%	-$0.22	-$0.27	-$2.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	8M+14.3%	7M-23.5%	10M-50.8%	19M	16M	1M	903,812-99.9%	1.10B+13.6%	969M+14.6%	845M+12.3%	752M+6.8%	704M+20.8%	583M+32.3%	441M	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Revenue	$0	N/A	$0	$0	$0	N/A	$0	$0
R&D Expenses	$60K-36.9%	N/A	$93K-21.2%	$141K+44.7%	$95K-0.9%	N/A	$118K-6.7%	$97K+18.8%
SG&A Expenses	$947K+25.7%	N/A	$2.0M+140.5%	$1.2M+22.4%	$753K-35.8%	N/A	$842K+234.3%	$1.0M+270.1%
Operating Income	-$1.0M-18.7%	N/A	-$2.1M-120.6%	-$1.4M-24.4%	-$848K+33.1%	N/A	-$960K+48.6%	-$1.1M+21.5%
Income Tax	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$5.1M+39.2%	N/A	$747K+124.5%	-$7.4M-404.8%	-$8.4M-135.7%	N/A	-$3.0M-391.5%	-$1.5M-152.7%
EPS (Basic)	-$0.54+56.1%	-$0.36-123.7%	-$0.17+61.4%	-$1.24-217.9%	-$1.23-164.7%	$1.52+560.6%	-$0.44+32.3%	-$0.39-50.0%
EPS (Diluted)	-$0.54+56.1%	-$0.36-123.7%	-$0.17+61.4%	-$1.24	-$1.23	$1.52+560.6%	-$0.44	-$0.39-50.0%
Diluted Shares (Avg)	11M+58.0%	N/A	9M+33.1%	7M	7M	N/A	7M	8M-12.9%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA, Interest Expense.

PMCB Balance Sheet

PMCB quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$46.8M-15.3%	$55.2M-7.9%	$59.9M-18.3%	$73.3M-19.1%	$90.6M+1124.0%	$7.4M+20.1%	$6.2M+6.6%	$5.8M-9.8%	$6.4M-26.0%	$8.7M+21.0%	$7.2M-23.0%	$9.3M-0.2%	$9.3M+223.8%	$2.9M+37.8%	$2.1M
Current Assets	$37.4M+67.2%	$22.4M-55.6%	$50.4M-26.0%	$68.1M-20.3%	$85.5M+3657.6%	$2.3M+119.3%	$1.0M+58.8%	$653K-49.1%	$1.3M-63.7%	$3.5M+74.2%	$2.0M-51.3%	$4.2M-0.4%	$4.2M+126.5%	$1.8M+74.6%	$1.1M
Cash & Equivalents	$18.6M+22.6%	$15.2M-69.8%	$50.2M-26.2%	$68.0M-20.3%	$85.4M+3778.1%	$2.2M+146.1%	$895K+73.7%	$515K-51.4%	$1.1M-69.4%	$3.5M+80.4%	$1.9M-28.9%	$2.7M-25.3%	$3.6M+1714.6%	$199K+1167.6%	$16K
Short-Term Investments	$254K-30.7%	$366K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$7K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$11.8M+259.2%	$3.3M-83.9%	$20.4M+3376.0%	$587K-16.7%	$704K-2.8%	$725K-32.7%	$1.1M+45.1%	$743K+15.3%	$644K+11.0%	$580K-9.0%	$638K-58.1%	$1.5M+306.9%	$374K-91.5%	$4.4M+0.3%	$4.4M
Current Liabilities	$826K-71.6%	$2.9M-60.7%	$7.4M+1165.2%	$587K-16.7%	$704K-2.8%	$725K-29.7%	$1.0M+38.8%	$743K+15.3%	$644K+11.0%	$580K-9.0%	$638K-58.1%	$1.5M+306.9%	$374K-90.2%	$3.8M+0.3%	$3.8M
Non-Current Liabilities	$10.9M+2915.4%	$363K-97.2%	$13.0M	$0	$0	$0-100.0%	$46K	$0	$0	$0	$0	$0	$0-100.0%	$580K0.0%	$580K
Total Equity	$33.3M-35.8%	$51.9M+87.7%	$27.6M-62.0%	$72.7M-19.2%	$89.9M+1246.2%	$6.7M+31.3%	$5.1M+1.0%	$5.0M-12.6%	$5.8M-28.7%	$8.1M+24.0%	$6.5M-16.1%	$7.8M-13.0%	$8.9M+695.6%	-$1.5M+34.1%	-$2.3M
Retained Earnings	-$104.4M-22.9%	-$85.0M+26.5%	-$115.6M+0.3%	-$116.0M-3.9%	-$111.6M-3.9%	-$107.4M-3.4%	-$103.9M-3.8%	-$100.0M-4.2%	-$96.0M-7.7%	-$89.1M-5.2%	-$84.7M-7.7%	-$78.6M-14.5%	-$68.7M-65.8%	-$41.4M-4.0%	-$39.8M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$36.7M-18.6%	$46.8M-15.3%	$55.9M+27.5%	$56.0M+1.6%	$45.1M-35.7%	$55.2M-7.9%	$43.8M-38.6%	$55.1M-30.1%
Current Assets	$31.0M+62.1%	$37.4M+67.2%	$20.7M+22.0%	$23.0M+7.9%	$19.1M-41.9%	$22.4M-55.6%	$17.0M-72.4%	$21.3M-71.1%
Cash & Equivalents	$17.7M+34.6%	$18.6M+22.6%	$20.2M+23.1%	$15.4M-26.1%	$13.2M-59.6%	$15.2M-69.8%	$16.4M-73.2%	$20.8M-71.6%
Short-Term Investments	$99K-62.0%	$254K-30.7%	$372K-0.1%	$201K	$262K	$366K	$373K	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.9M+354.1%	$11.8M+259.2%	$16.5M+360.3%	$19.4M+66.8%	$1.5M-91.1%	$3.3M-83.9%	$3.6M-91.1%	$11.6M-72.3%
Current Liabilities	$769K-27.5%	$826K-71.6%	$1.7M+40.5%	$1.6M-67.0%	$1.1M-85.8%	$2.9M-60.7%	$1.2M-84.2%	$4.8M-8.8%
Non-Current Liabilities	$6.1M+1238.0%	$10.9M+2915.4%	$14.8M+520.5%	$17.8M+159.7%	$458K-95.3%	$363K-97.2%	$2.4M-92.7%	$6.9M-81.4%
Total Equity	$27.5M-36.9%	$33.3M-35.8%	$38.1M-5.3%	$35.2M-18.9%	$43.6M-8.6%	$51.9M+87.7%	$40.3M+28.3%	$43.5M+18.2%
Retained Earnings	-$109.5M-17.3%	-$104.4M-22.9%	-$100.0M-3.4%	-$100.7M-7.6%	-$93.3M-1.2%	-$85.0M+26.5%	-$96.7M+17.3%	-$93.7M+19.5%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PMCB Cash Flow Statement

PMCB quarterly cash flow statement

Metric	TTM	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$3.9M	-$5.2M-73.0%	-$3.0M-38.4%	-$2.2M+43.3%	-$3.8M+7.9%	-$4.1M-23.6%	-$3.3M-42.4%	-$2.3M+18.7%	-$2.9M+43.3%	-$5.1M-52.1%	-$3.3M+23.2%	-$4.3M+4.7%	-$4.6M-193.3%	-$1.6M-298.2%	-$390K-50.6%	-$259K
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$25K
Stock-Based Compensation	N/A	$893K	$0-100.0%	$675K+9099.5%	$7K-77.9%	$33K-82.9%	$194K-47.3%	$369K+25.7%	$293K-49.5%	$580K+38.0%	$420K+3.8%	$405K-44.9%	$735K	$0	$0-100.0%	$1.6M
Investing Cash Flow	N/A	$2.0M+128.6%	-$7.0M-40.0%	-$5.0M	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	-$647K+25.8%	-$872K
Financing Cash Flow	$6.5M	$6.6M+126.3%	-$25.0M-133.7%	-$10.7M+21.0%	-$13.6M-115.5%	$87.3M+1783.0%	$4.6M+70.1%	$2.7M+16.4%	$2.3M-12.6%	$2.7M-45.1%	$4.9M	N/A	N/A	N/A	$1.2M+12.0%	$1.1M
Share Buybacks	N/A	$402K-84.2%	$2.5M-91.0%	$28.2M+107.9%	$13.6M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$781K+60.8%	-$1.4M-33.9%	-$787K-54.3%	-$980K+7.1%	-$2.0M-434.2%	-$1.0M-212.5%	-$510K-187.9%	-$1.1M+46.8%
Stock-Based Compensation	N/A	N/A	N/A	N/A	$60K-72.8%	N/A	N/A	N/A
Investing Cash Flow	N/A	$0	$5.0M	-$3.0M	$0+100.0%	$0	$0+100.0%	$0
Financing Cash Flow	-$83K	-$170K+1.0%	$544K+113.8%	$6.2M+157.8%	$0+100.0%	-$172K+98.4%	-$3.9M+43.9%	-$10.7M-1534.6%
Share Buybacks	N/A	$0-100.0%	$402K+78.5%	$0-100.0%	$0-100.0%	$172K-85.4%	$225K-44.4%	$1.4M+750.9%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid.

PMCB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PMCB quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	20.9%-50.0pp	70.9%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-13851.7%	-2928.5%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-13142.3%	-2853.6%
Return on Equity	-58.3%-117.4pp	59.1%+57.9pp	1.2%+7.2pp	-5.9%-1.2pp	-4.7%+48.5pp	-53.2%+22.0pp	-75.2%+5.5pp	-80.7%+37.7pp	-118.4%-63.4pp	-54.9%+38.0pp	-93.0%+34.7pp	-127.6%+177.1pp	-304.8%	N/A	N/A
Return on Assets	-41.5%-97.1pp	55.6%+55.0pp	0.6%+6.5pp	-5.9%-1.2pp	-4.7%+43.3pp	-48.0%+14.1pp	-62.1%+8.3pp	-70.3%+36.1pp	-106.5%-55.2pp	-51.3%+33.4pp	-84.7%+22.1pp	-106.8%+185.8pp	-292.6%-237.0pp	-55.5%+35.4pp	-91.0%
Current Ratio	45.28+37.6x	7.68+0.9x	6.80-109.4x	116.18-5.2x	121.38+118.2x	3.14+2.1x	1.01+0.1x	0.88-1.1x	1.99-4.1x	6.10+2.9x	3.19+0.4x	2.74-8.5x	11.20+10.7x	0.49+0.2x	0.28
Debt-to-Equity	0.35+0.3x	0.06-0.7x	0.74+0.7x	0.010.0x	0.01-0.1x	0.11-0.1x	0.21+0.1x	0.150.0x	0.110.0x	0.070.0x	0.10-0.1x	0.20+0.2x	0.04	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.03

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Return on Equity	-18.5%+0.7pp	N/A	2.0%+9.5pp	-21.1%-17.7pp	-19.2%-68.3pp	N/A	-7.6%-5.6pp	-3.4%-11.0pp
Return on Assets	-13.8%+4.7pp	N/A	1.3%+8.3pp	-13.3%-10.6pp	-18.5%-51.9pp	N/A	-7.0%-6.1pp	-2.7%-6.2pp
Current Ratio	40.30+22.3x	45.28+37.6x	12.33-1.9x	14.60+10.1x	18.01+13.6x	7.68+0.9x	14.20+6.0x	4.47-9.6x
Debt-to-Equity	0.25+0.2x	0.35+0.3x	0.43+0.3x	0.55+0.3x	0.03-0.3x	0.06-0.7x	0.09-1.2x	0.27-0.9x
Asset Turnover	0.000.0x	N/A	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PharmaCyte Biotech, Inc. PMCB	FY2026	$0	-$19.4M	N/A	$3.9M	—
TNF Pharmaceuticals, Inc. TNFA	FY2025	N/A	-$11.6M	N/A	$9.6M	—
HCW Biologics Inc. HCWB	FY2025	$54K	-$8.0M	N/A	$3.3M	—
AIM ImmunoTech Inc. AIM	FY2025	$88K	-$14.0M	N/A	$7.2M	—
CERO TERAPEUTICS HLDG INC CERO	FY2025	N/A	N/A	N/A	$177K	—

Where PharmaCyte Biotech, Inc. Ranks

Frequently Asked Questions

What is PharmaCyte Biotech, Inc.'s annual revenue?

PharmaCyte Biotech, Inc. (PMCB) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is PharmaCyte Biotech, Inc. profitable?

No, PharmaCyte Biotech, Inc. (PMCB) reported a net income of -$19.4M in fiscal year 2026.

What is PharmaCyte Biotech, Inc.'s return on equity (ROE)?

PharmaCyte Biotech, Inc. (PMCB) has a return on equity of -58.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is PharmaCyte Biotech, Inc.'s operating cash flow?

PharmaCyte Biotech, Inc. (PMCB) recorded an outflow of $5.2M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are PharmaCyte Biotech, Inc.'s total assets?

PharmaCyte Biotech, Inc. (PMCB) had $46.8M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does PharmaCyte Biotech, Inc. spend on research and development?

PharmaCyte Biotech, Inc. (PMCB) invested $391K in research and development during fiscal year 2026.

Does PharmaCyte Biotech, Inc. buy back shares?

Yes, PharmaCyte Biotech, Inc. (PMCB) spent $402K on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does PharmaCyte Biotech, Inc. have outstanding?

PharmaCyte Biotech, Inc. (PMCB) had 11M shares outstanding as of fiscal year 2026.

What is PharmaCyte Biotech, Inc.'s current ratio?

PharmaCyte Biotech, Inc. (PMCB) had a current ratio of 45.28 as of fiscal year 2026, which is generally considered healthy.

What is PharmaCyte Biotech, Inc.'s debt-to-equity ratio?

PharmaCyte Biotech, Inc. (PMCB) had a debt-to-equity ratio of 0.35 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is PharmaCyte Biotech, Inc.'s return on assets (ROA)?

PharmaCyte Biotech, Inc. (PMCB) had a return on assets of -41.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is PharmaCyte Biotech, Inc.'s P/E ratio?

PharmaCyte Biotech, Inc. (PMCB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $3.9M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PharmaCyte Biotech, Inc.'s price-to-sales ratio?

PharmaCyte Biotech, Inc. (PMCB) has no price-to-sales ratio at the moment: revenue is not positive (FY2026). The market capitalization is $3.9M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does PharmaCyte Biotech, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, PharmaCyte Biotech, Inc. (PMCB) held $18.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.2M over that year. Dividing the one by the other, the reported balance equals about 44 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is PharmaCyte Biotech, Inc.'s Altman Z-Score?

PharmaCyte Biotech, Inc. (PMCB) has an Altman Z-Score of -2.47, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is PharmaCyte Biotech, Inc.'s Piotroski F-Score?

PharmaCyte Biotech, Inc. (PMCB) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PharmaCyte Biotech, Inc.'s earnings high quality?

PharmaCyte Biotech, Inc. (PMCB) reported a net loss of $19.4M while operations used $5.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.